Modified Therapeutic Antibodies: Improving Efficacy
The prosperity of the biotherapeutics market reflects the feasibility and effectiveness of therapeutic antibodies for the treatment of cancers, inflammatory disorders, and refractory infections. As drawbacks emerge in clinical trials and practice, such as impeded binding, reduced effector functions,...
Main Authors: | Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-11-01
|
Series: | Engineering |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095809921003040 |
Similar Items
-
Therapeutic Antibodies in Cancer Treatment in the UK
by: Khadiga Eltarhoni, et al.
Published: (2022-11-01) -
Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01) -
Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01) -
Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
by: Suheil Albert Atallah-Yunes, et al.
Published: (2022-01-01) -
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
by: Hyunbo Shim
Published: (2020-02-01)